SENSORS | ARTICLE
<< Figure 3: Te I-35W Bridge spanning the Mississippi River in Minneapolis, Minnesota, collapsed in 2007 killing 13 and injuring 145. Analysis of the catastrophe reported that “an inadequate use of technologies for accurately assessing the condition of the gusset plates on the deck truss” was one of several major reasons for the collapse. >>
http://www.mancef.org
Next-Gen Pharmaceutical Industry Landscape
Presented by MANCEF and contributed to by professionals around the world, Emerging Technology roadmapping has evolved. The pharmaceutical industry - like many other industries - is being redefined by exceptional changes in its manufacturing processes. Pharma has switched, from being a single root technology based solution, to multiple technology based solutions.
Today, pharmaceutical solutions are not simply based on a single chemical isomer but are more often based on multiple technologies. These include: nanotechnology, MEMS, tissue engineering, complex chemistries, and computational sciences. How can companies, technologists, investors, policy makers, marketing professionals and entrepreneurs make decisions about the future? The answer requires a deeper understanding of a new roadmapping process – Landscaping. Market, technical, and social drivers are much more important in today’s pharmaceutical landscape.
Modern pharmaceutical solutions rely on advances in at least five technological pathways. Many traditional roadmapping methods assume a unit product and a single technological pathway with a single technology trajectory. These, however, are not useful for pharmaceutical landscaping.
A 3rd generation model is required to develop a meaningful roadmapping process: one that is focused on drivers. In this version, 18 technological, market, regulatory, and manufacturing drivers are identified. The model takes account of the industry’s new structure.
The Pharmaceutical Landscape has over 350 pages and describes in detail all drivers, technology subcomponents, and a process that will enable readers to develop their own internal roadmaps. The role of consortia, which, since 1990, have increased from five to over 100 is described. Numerous networks, partnerships and companies currently involved in the industry are identified.
Only USD 250 For more details please contact Rob Haak at
rhaak@mancef.org 44 | commercial micro manufacturing international Vol 7 No.6
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52